Showing results (1341-1350 of 1,518) with videos related to
Sort By:
Pageof 152
Biorxiv : the Preprint Server for Biology|February 20, 2025
TRAF6 integrates innate immune signals to regulate glucose homeostasis via Parkin-dependent and -independent mitophagyElena Levi-D'Ancona, Emily M Walker, Jie Zhu, et al.Dermatitis : Contact, Atopic, Occupational, Drug|December 4, 2020
Fragrance- and Botanical-Related Allergy and Associated Concomitant Reactions: A Retrospective Analysis of the North American Contact Dermatitis Group Data 2007-2016Amber Reck Atwater, Jordan Maxwell Ward, Beiyu Liu, et al.The New England Journal of Medicine|June 5, 2018
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCMark A Socinski, Robert M Jotte, Federico Cappuzzo, et al.Ebiomedicine|November 8, 2020
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNASteffen Dietz, Petros Christopoulos, Zhao Yuan, et al.The Lancet. Oncology|June 6, 2015
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trialNick Thatcher, Fred R Hirsch, Alexander V Luft, et al.Kidney International Reports|July 18, 2025
Urinary Clusterin is a Biomarker of Renal Epithelial Senescence and Predicts Human Kidney Disease ProgressionDavid P Baird, Maximilian Reck, Ross Campbell, et al.Biorxiv : the Preprint Server for Biology|June 12, 2026
The structural basis for LRRK2's activation and autoinhibitionAmalia Villagran Suarez, Kathryn S Hatch, Tatyana Bodrug, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 31, 2016
Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of TreatmentCorey J Langer, Coleman Obasaju, Paul Bunn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancerGiorgio Scagliotti, Silvia Novello, Joachim von Pawel, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2017
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung CancerMartin Reck, Normand Blais, Erzsebet Juhasz, et al.Pageof 152